Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 801–900 of 1,002
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers
Drobner, J. C., Doppalapudi, K., Saraiya, B., Packiam, V. T., & Ghodoussipour, S. B. (2024) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.6.078 · Cited by 15
PD-1 Blockade in Mismatch Repair–Deficient Rectal Cancer
Copur, M. S., Tun, S. M., & Duckert, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2209706 · Cited by 12
Lou, J., Xiang, Z., Zhu, X., Fan, Y., Li, J., Jin, G., Cui, S., Huang, N., & Le, X. (2024) · Medicine · doi:10.1097/md.0000000000040432 · Cited by 15
Exploring the role of gut microbiota in colorectal liver metastasis through the gut-liver axis
Liu, Q.-L., Zhou, H., Wang, Z., & Chen, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1563184 · Cited by 14
Feigenberg, S. J., Costabile, F., Tanes, C., Bittinger, K. L., O'Connor, R., Agarwal, D., Skoufos, G., Salaris, S., Hatzigeorgiou, A. G., Κωστόπουλος, Ν., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011356 · Cited by 15
Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma
Chen, P., Devkota, S., Shiao, S. L., Hendifar, A. E., & Yang, J. D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1568962 · Cited by 13
Intratumoral microbiome: the double-edged sword in remodeling cancer immunotherapy
Yan, D., Yu, Y., Liang, C., Cui, Z., Shi, L., Li, G., & Ren, C. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02566-6 · Cited by 11
Wang, X., He, J., Ding, G., Tang, Y., & Wang, Q. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s572089 · Cited by 13
Han, X., Zang, D., Liu, D., & Chen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988849 · Cited by 12
Du, P., Jing, J., & He, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1091124 · Cited by 15
Emerging applications of cancer bacteriotherapy towards treatment of pancreatic cancer
Henderson, E. A., Łukomski, S., & Boone, B. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1217095 · Cited by 14
Lu, G., Zhang, S., Wang, R., Zhang, Z., Wang, W., Wen, Q., Zhang, F., & Li, P. (2023) · Nutrients · doi:10.3390/nu15173704 · Cited by 13
The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications
Zhou, Y., Liu, X., Gao, W., Luo, X., Lv, J., Wang, Y., & Liu, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23919 · Cited by 13
Gut microbiome as a treatment in colorectal cancer
Khan, M., Shah, S., Shah, W., Khan, I., Ali, H., Ali, I., Ullah, R., Wang, X., Mehmood, A., & Wang, Y. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2312294 · Cited by 13
Self-citationSystemic metabolic depletion of gut microbiome undermines responsiveness to melanoma immunotherapy
Zakharevich, N. V., Morozov, M. D., Kanaeva, V. A., Filippov, M. S., Zyubko, T., Ivanov, A. B., Игоревич, У. В., Klimina, K. M., & Olekhnovich, E. I. (2024) · Life Science Alliance · doi:10.26508/lsa.202302480 · Cited by 12
Metastasis and the Microbiome: The Impact of Bacteria in Disseminated Colorectal Cancer
Ayabe, R. I., & White, M. G. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904152 · Cited by 14
Therapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities
Lee, J. B., Huang, Y., Oya, Y., Nützinger, J., Ang, Y. L. E., Sooi, K. W. X., Cho, B. C., & Soo, R. A. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107862 · Cited by 13
Exploring the virome: An integral part of human health and disease
Gholamzad, A., Khakpour, N., Hashemi, S. M. A., Goudarzi, Y., Ahmadi, P., Gholamzad, M., Mohammadi, M., & Gholamzad, M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155466 · Cited by 14
Yin, Q., Ni, J., & Ying, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1263 · Cited by 13
Yu, Z., Wang, Q., Wang, Z., Liu, S., Xia, T., Duan, C., Liu, Y., Ding, X., Chen, S., Yu, T., et al. (2024) · Head & Neck · doi:10.1002/hed.27917 · Cited by 14
Therapeutic Modulation of the Microbiome in Oncology: Current Trends and Future Directions
Saraswat, I., & Goel, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010353600241109132441 · Cited by 15
Identification of intratumoral bacteria that enhance breast tumor metastasis
Gerbec, Z. J., Serapio-Palacios, A., Metcalfe‐Roach, A., Krekhno, Z., Bar‐Yoseph, H., Woodward, S. E., Peña-Díaz, J., Nemirovsky, O., Awrey, S. J., Moreno, S. H., et al. (2025) · mBio · doi:10.1128/mbio.03595-24 · Cited by 16
Chen, Y., Wu, J., Cai, K., Xiao, X., Chen, Y., Zhang, X., Deng, S., Pei, C., Chen, Y., Xie, Z., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114283 · Cited by 11
Nutrition and Diet Patterns as Key Modulators of Metabolic Reprogramming in Melanoma Immunotherapy
Grafanaki, K., Maniatis, A., Anastogianni, A., Bania, A., Pasmatzi, E., & Stathopoulos, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124193 · Cited by 13
Ecological management of the microbiota in patients with cancer
Xavier, J. B. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01049-3 · Cited by 18
The gut-tumor connection: the role of microbiota in cancer progression and treatment strategies
Wei, Z., Gao, G., He, Q., Kwok, L. Y., & Sun, Z. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.038 · Cited by 14
Targeting the Microbiome to Overcome Resistance
Simpson, R. C., Shanahan, E. R., Scolyer, R. A., & Long, G. V. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.016 · Cited by 11
The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
Jasiński, M., Biliński, J., & Basak, G. W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741376 · Cited by 11
Evolution of FMT – From early clinical to standardized treatments
Servetas, S. L., Daschner, P. J., Guyard, C., Thomas, V., Affagard, H., Sergaki, C., Sokol, H., Wargo, J. A., Wu, G. D., & Sabot, P. (2022) · Biologicals · doi:10.1016/j.biologicals.2022.01.004 · Cited by 12
Self-citationKamiya, T., & Ohtani, N. (2022) · International Immunology · doi:10.1093/intimm/dxac020 · Cited by 12
Lipids from gut microbiota: pursuing a personalized treatment
Carneiro, P. V., Montenegro, N. D. A., Lana, A. J., Amato, A. A., & Santos, G. M. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.06.001 · Cited by 13
Complex Role of Microbiome in Pancreatic Tumorigenesis: Potential Therapeutic Implications
Amara, S., Yang, L. V., Tiriveedhi, V., & Muzaffar, M. (2022) · Cells · doi:10.3390/cells11121900 · Cited by 12
Domingues, C., Cabral, C., Jarak, I., Veiga, F., Dourado, M., & Figueiras, A. (2023) · Vaccines · doi:10.3390/vaccines11030492 · Cited by 13
Radiation Therapy and the Microbiome; More Than a Gut Feeling
Amit, U., Facciabene, A., & Ben‐Josef, E. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000650 · Cited by 11
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity
Yang, L., Li, S., Chen, L., & Zhang, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0241 · Cited by 16
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
Jang, A., Lichterman, J. N., Zhong, J. Y., Shoag, J. E., Garcia, J. A., Zhang, T., & Barata, P. C. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2276629 · Cited by 13
Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches
Tabolacci, C., Cordella, M., Rossi, S., Bonaccio, M., Eramo, A., Mischiati, C., Beninati, S., Iacoviello, L., Facchiano, A., & Facchiano, F. (2021) · Molecules · doi:10.3390/molecules26123619 · Cited by 12
Moyers, J. T., & Oliva, I. C. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_3 · Cited by 13
Makunts, T., Burkhart, K., Abagyan, R. A., & Lee, P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263402 · Cited by 10
Chen, Y., & Lai, X. (2022) · Mathematical Biosciences · doi:10.1016/j.mbs.2022.108868 · Cited by 12
Rühle, A., Zou, J., Glaser, M., Halle, L., Gkika, E., Schäfer, H. S., Knopf, A., Becker, C., Grosu, A., Popp, I., et al. (2023) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-023-07868-3 · Cited by 16
Host-microbiota interactions in genitourinary cancer immunotherapy
Xu, X., Cui, J., Li, W., Xu, Y., Yuan, S., Zeng, X., & Li, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.005 · Cited by 12
Microbial metabolites for cancer immunotherapy: Current evidence and future directions
Wang, X., Liang, J.-J., Duan, X., & Chen, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.005 · Cited by 12
From Dysbiosis to Diagnosis: The Role of Gut Microbiota in Breast Cancer Etiology and Management
Mishra, P., Mishra, S. P., Pattnaik, A., Singh, S., Shakri, A. R., Badhai, J., Ganguly, S., Guria, A., & Cheekatla, S. S. (2025) · Applied Microbiology · doi:10.3390/applmicrobiol5040134 · Cited by 15
Huang, H., Peng, S., Liu, Y., Chen, L., & Wu, F. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07885-w · Cited by 11
Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer
Park, U., Heo, J.-Y., Chun, S.-M., Lee, J.-C., Lee, S.-H., & Lee, S.-W. (2026) · Immune Network · doi:10.4110/in.2026.26.e7 · Cited by 11
Leung, E. L., Huang, J., Zhang, J., Zhang, J., Wang, M., Zhu, Y., Meng, Z., Yu, H., Neher, E., Ma, L., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0243 · Cited by 14
Liu, L., Hao, X., Bai, Y., & Tian, Y. (2024) · Aging Cell · doi:10.1111/acel.14416 · Cited by 20
Exploring micronutrients and microbiome synergy: pioneering new paths in cancer therapy
Bhatnagar, K., Jha, K., Dalal, N., Patki, N., Gupta, G., Kumar, A., Kumar, A., & Chaudhary, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1442788 · Cited by 12
Laurent, P.-A., André, F., Bobard, A., Deandreis, D., Demaria, S., Depil, S., Eichmüller, S. B., Fernández-Palomo, C., Foijer, F., Galluzzi, L., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2432726 · Cited by 10
A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy
Kim, C. Y., Park, D. J., Ahn, B., Baek, S., Hong, M. H., Nguyen, L. T., Hwang, S. H., Kim, N., Podlesny, D., Orakov, A. N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55388-3 · Cited by 12
Bruno, P. S., Biggers, P., Nuru, N., Versaci, N., Chirila, M. I., Darie, C. C., & Neagu, A.-N. (2025) · Biomedicines · doi:10.3390/biomedicines13030665 · Cited by 11
Cell Death Modalities in Therapy of Melanoma
Wang, M., Zhao, J., Tang, M.-X., Li, M., Zhao, H., Li, Z., & Liu, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083475 · Cited by 11
Expanding horizons of cancer immunotherapy: hopes and hurdles
Sonar, P. V., Singh, A. K., Mandadi, S., & Sharma, N. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1511560 · Cited by 12
Gut microbiome and colorectal cancer: From pathogenesis to treatment
Lahouty, M., Fadaee, M., Aghaei, R., Alizadeh, F., Jafari, A., & Sharifi, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156034 · Cited by 11
Critical Role of Skin in Pathogenesis: Bidirectional Crosstalk Between Skin and Multiple Organs
Deng, W., Liu, J., Tang, C., Li, Z., Qiu, Y., Zhou, H., Yang, L., & Li, T. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70020 · Cited by 10
Wang, F., Chen, W., Jia, Y., He, T., Wu, S., Xiang, J., Chen, R., Jiang, Q., Yu, T., Lan, Y., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70994 · Cited by 17
Pamungkas, K. M. N., Dewi, P. I. S. L., Alamsyah, A. Z., Dewi, N. L. P. Y., Dewi, N. N. G. K., Mariadi, I. K., & Sindhughosa, D. A. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106810 · Cited by 11
Dayhimi, A., Jazi, K., Bigdeli, Y., Farhoudi, F., Erfanimanesh, M., Esmaeili, M., Gorjipour, F., Ajami, M., & Pazoki–Toroudi, H. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251365700 · Cited by 14
Immunotherapy response-associated Akkermansia: canary in a coal mine?
Cascone, T., Chelvanambi, M., & Wargo, J. A. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.03.007 · Cited by 10
Self-citationIsozaki, S., Konishi, H., Tanaka, H., Yamamura, C., Moriichi, K., Ogawa, N., & Fujiya, M. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02530-0 · Cited by 11
Robinson, I., Hochmair, M. J., Schmidinger, M., Absenger, G., Pichler, M., Nguyen, V. A., Richtig, E., Rainer, B. M., Ay, L., Jansen, C., et al. (2023) · Cancers · doi:10.3390/cancers15133268 · Cited by 12
Zhong, J., Xiong, D., Liu, Y., & Yuan, S. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15172 · Cited by 12
Personalizing Oncolytic Immunovirotherapy Approaches
Stergiopoulos, G. M., Iankov, I. D., & Galanis, E. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00689-4 · Cited by 10
Microbiome modification for personalized treatment of dysbiotic diseases
Sartor, R. B. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.023 · Cited by 10
Roberto, M., Carconi, C., Cerreti, M., Schipilliti, F. M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704942 · Cited by 10
Understanding resistance to immune checkpoint inhibitors in advanced breast cancer
Tarantino, P., Barroso‐Sousa, R., Garrido-Castro, A. C., McAllister, S. S., Guerriero, J. L., Mittendorf, E. A., Curigliano, G., & Tolaney, S. M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2020650 · Cited by 10
Li, P., Gao, M., Song, B., Liu, Y., Yan, S., Lei, J., Zhao, Y., Li, G., Mahmood, T., Lv, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884615 · Cited by 11
Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma
Nakamura, K., & Okuyama, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112991 · Cited by 10
Limeta, A., Gatto, F., Herrgård, M. J., Ji, B., & Nielsen, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.07.032 · Cited by 9
Kadhim, A. S., & Al-Karawi, A. S. (2023) · American Journal of Bioscience and Bioinformatics · doi:10.54536/ajbb.v2i1.1910 · Cited by 14
Gao, X., & Jiang, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1359029 · Cited by 12
Microbial Advancement in Agriculture
Upadhayay, V. K., Santos‐Villalobos, S. D. L., Aravindharajan, S. T. M., Kukreti, B., Chitara, M. K., Jaggi, V., Sharma, A., & Singh, A. V. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-0633-4_5 · Cited by 9
Potential of Synbiotics and Probiotics as Chemopreventive Agent
Chin, K. W., Khoo, S. C., Paul, R. P. M., Luang‐In, V., Lam, S. D., & Ling, N. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10299-z · Cited by 12
Microbiota-metabolism-epigenetics-immunity axis in cancer
Ren, B., Fang, Y., Gu, M., You, L., Zhang, T., & Zhao, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1449912 · Cited by 10
Molecular Susceptibility and Treatment Challenges in Melanoma
Shenoy, P. V., Nag, R., Kolathur, K. K., Malik, Y., Varanasi, S. M., Angom, R. S., & Mukhopadhyay, D. (2024) · Cells · doi:10.3390/cells13161383 · Cited by 12
Targeting the gut and tumor microbiome in cancer treatment resistance
Čierniková, S., Ševčíková, A., & Mego, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00201.2024 · Cited by 12
Hrubesz, G., Leigh, J., & Ng, T. L. (2024) · Translational Breast Cancer Research · doi:10.21037/tbcr-24-14 · Cited by 11
From Gut to Brain: The Impact of Short-Chain Fatty Acids on Brain Cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Sanghvi, G. V., Menon, S. V., Sharma, P., Tomar, B. S., Sharma, A., Sameer, H. N., Hamad, A. K., et al. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08830-8 · Cited by 10
Friends close, enemies closer: the complex role of the microbiome in antitumor immunity
Patra, D., Dev, G., Hand, T. W., & Overacre-Delgoffe, A. E. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102537 · Cited by 11
Golomb, S. M., Guldner, I. H., Aleksandrovic, E., Fross, S. R., Liu, X., Diao, L., Liang, K., Wu, J., Wang, Q., Lopez, J. A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115356 · Cited by 11
Li, Y., Feng, Z., Liang, C., Lu, S., Wang, G., & Meng, G. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03819-w · Cited by 9
Gut reactions: harnessing microbial metabolism to fuel next-generation cancer immunotherapy
Almonte, A. A., & Zitvogel, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011540 · Cited by 9
Gencel, M., Cofino, G. M., Hui, C., Sahaf, Z., Gauthier, L., Matta, C., Gagné-Leroux, D., Tsang, D. K. L., Philpott, D. J., Ramathan, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61368-y · Cited by 10
Xian, Y., Chen, Z., Lan, Z., Zhang, C., Sun, H., Liu, Z., Kong, P., Liang, Y., Zhao, Y., Liu, S. M., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2557978 · Cited by 12
Akabane, M., Imaoka, Y., Lee, G. R., & Pawlik, T. M. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2568904 · Cited by 10
Communication between gut microbiota-derived metabolites and the tumor microenvironment
Hu, X., Li, B., Li, Y., Liang, Y., & Huang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1649438 · Cited by 11
The role of gut mycobiome in responses to cancer immunotherapy
Szóstak, N., Kozłowski, P., Zuo, T., & Philips, A. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2571433 · Cited by 13
Advances in Nanomedicine-Mediated Modulation of the Microbiome for Cancer Therapy
Huang, Y., Zhang, Z., Xue, L., Zhang, X., & He, C. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s558099 · Cited by 10
Design and application of synthetic human gut microbial communities
Kim, M. S., & Bisanz, J. E. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2575923 · Cited by 10
Chen, M., Zhou, J., Wu, C., Zhang, W., Long, F., Zhou, S.-S., Xu, J., Wu, J., Zou, Y., Li, S., et al. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123136 · Cited by 9
Wang, X., Wu, C., & Wei, H. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0039 · Cited by 9
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment
Lopez, S. H., Jalving, M., Fehrmann, R. S. N., Nagengast, W. B., de Vries, E. G. E., & de Haan, J. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102406 · Cited by 9
In vitro fermentation of pretreated oat bran by human fecal inoculum and impact on microbiota
Bai, X., Zhang, M., Zhang, Y., Zhang, Y., Huo, R., & Guo, X. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105278 · Cited by 9
Role of Gut Microbiome in Immune Regulation and Immune Checkpoint Therapy of Colorectal Cancer
Shi, L., Xu, Y., & Feng, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07689-0 · Cited by 9
Neoadjuvant Immunotherapy in Early, Triple-Negative Breast Cancers: Catching Up with the Rest
Kim, L., Coman, M., Pusztai, L., & Park, T. S. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13714-x · Cited by 9
Elucidating the roles of the mammary and gut microbiomes in breast cancer development
Hoskinson, C., Jiang, R., & Stiemsma, L. T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1198259 · Cited by 13
Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
Gabrielli, G., Shouval, R., Ghilardi, G., van den Brink, M. R. M., & Ruella, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000950 · Cited by 11
Verhoef, J. I., Klont, E., van Overveld, F. J., & Rijkers, G. T. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2262765 · Cited by 9
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.